A panel of 266 clinically isolated Gram-positive cocci and Gram-negative bacilli with varying levels of resistance to ciprofloxacin were analysed for susceptibility to Du-6859a, ciprofloxacin, ofloxacin, temafloxacin and nalidixic acid. Staphylococci were divided into ciprofloxacin-susceptible, moderately resistant and highly resistant subgroups. Du-6859a was the most potent quinolone against all taxa. As ciprofloxacin resistance increased to high levels, MICs of all quinolones increased but Du-6859a MICs increased least, and ciprofloxacin MICs increased most. Less susceptible single-step mutants were selected from 80% of 15 representative clinical isolates exposed to ciprofloxacin, 71% of isolates exposed to temafloxacin, 67% of isolates exposed to Du-6859a and 53% of isolates exposed to ofloxacin. Du-6859a inhibited more mutants (67%) at a concentration of 1 mg/L than did the other quinolones (26-43%) at their susceptible breakpoints. Du-6859a was the most rapidly bactericidal quinolone in time-kill studies with Enterococcus faecalis and Enterococcus faecium. This study indicated that Du-6859a is more potent than the comparator quinolones, is less affected by the mechanisms responsible for high-level quinolone resistance and may be less likely to select resistant mutants if it has a susceptible breakpoint of 1 mg/L.
Introduction
Increasing bacterial resistance to currently available quinolones has reduced their effectiveness and may compromise future use of this important class of antibacterial drugs. Of various proposals to limit the spread of quinolone resistance, the only factor that has been examined in detail is drug potency. 1 Spontaneous mutations that reduce quinolone susceptibility usually result in only modest increases in MIC (two-to eight-fold) and occur at low frequency. [2] [3] [4] Therefore, the bacteria that are most likely to develop quinolone resistance in a single mutational step are those for which fluoroquinolone MICs are high in the susceptible range, i.e. eight-fold or less below the susceptible breakpoint. This implies that the likelihood of resistance emerging can be reduced by use of fluoroquinolones of potency sufficient to inhibit both the pathogen infecting a patient and the less susceptible single-step mutant which may also be present or may emerge during therapy. 5, 6 For this reason, a study was designed to compare the activities of four quinolones against clinical and laboratory isolates that possess varying levels of resistance to ciprofloxacin and also to investigate the potential of the quinolones to select resistant mutants.
Materials and methods

Strains
Two hundred and sixty-six strains of Gram-positive and Gram-negative bacteria with different levels of resistance to ciprofloxacin were recovered from patients throughout the USA, Spain, Sweden, the UK and Australia. The clinical strains were chosen for their different levels of resistance to ciprofloxacin. They were not random clinical isolates. An additional isogenic panel of strains of Escherichia coli was tested to determine the effects of specific mutations on the activity of the study quinolones.
Susceptibilities
Antibiotic susceptibilities were determined by agar dilution testing with Mueller-Hinton agar and an inoculum of 10 4 cfu per spot. 7 This medium was supplemented with 4% NaCl when staphylococci were tested against oxacillin, and with 5% defibrinated sheep blood when Streptococcus pneumoniae was tested. Tests with S. pneumoniae were incubated in 10% CO 2 in air. Antibiotic solutions were prepared on the day of use from the following reference powders: Du-6859a (Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan), temafloxacin (Abbott Laboratories, Chicago, IL, USA), ofloxacin (R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA), ciprofloxacin (Bayer, Inc., West Haven, CT, USA), and nalidixic acid (Sigma Chemical Co., St Louis, MO, USA).
The staphylococci were separated into three phenotypic groups on the basis of their susceptibility to ciprofloxacin: susceptible (MIC 0.25 mg/L), moderately resistant (MIC 0.5-4 mg/L), and highly resistant (MIC 8 mg/L). 9 cfu were added to Mueller-Hinton agar or Todd-Hewitt agar (S. pneumoniae) containing superinhibitory concentrations (2-16 times the MIC) of antibiotic. The actual inoculum used was determined by agar dilution plate counts. After 48-72 h of incubation at 35°C in air (with 10% CO 2 added for S. pneumoniae), mutational frequencies were calculated from the results obtained for plates containing the highest drug concentration on which colonies were obtained. The colonies selected by this procedure were tested for their antibiotic susceptibilities as described above.
Mutational frequencies
Time-kill studies
The bactericidal activity of Du-6859a, ofloxacin and ciprofloxacin against E. faecalis 103 and E. faecium 129 was investigated in time-kill experiments. Stationary phase cultures were exposed to each quinolone at multiples of 0.5, 1 and 4 the MIC, and subcultured for viable counts at 0, 2, 4, 6 and 24 h on to Mueller-Hinton agar containing 5 mM FeCl 3 to overcome the effect of drug carryover. The viable counts were compared with those of drug-free control cultures.
Results
In-vitro activity
Du-6859a was the most potent quinolone overall (Table I) . It was at least four times more potent than each of the other quinolones against staphylococci, enterococci, pneumococci, members of the family Enterobacteriaceae, Acinetobacter spp., S. maltophilia, Chrysobacterium spp. and B. cepacia. Ciprofloxacin was similar to Du-6859a in potency against ciprofloxacin-susceptible and intermediate isolates of P. aeruginosa (ciprofloxacin MICs 2 mg/L), but four times less potent against the most resistant isolates. The numbers of isolates requiring >1 mg/L of Du-6859a or ciprofloxacin, or >2 mg/L of ofloxacin or temafloxacin for inhibition are shown in Table  II . The percent of isolates inhibited by these concentrations was 91% for Du-6859a, 70% for temafloxacin, 63% for ofloxacin and 55% for ciprofloxacin. Resistance to 1 mg/L of Du-6859a occurred in P. aeruginosa (eight isolates), S. aureus (six isolates), coagulase-negative staphylococci (two isolates), Acinetobacter spp. (five isolates), E. coli (two isolates) and E. faecium (one isolate).
Studies with the isogenic panel of strains of E. coli (Table III) indicated that the activity of Du-6859a was not reduced by specific mutations in gyrase subunit A (nalA), gyrase subunit B (nalC and nalD), or a purported impermeability mutation (nalB). In contrast, four-fold or greater increases in MICs of the other quinolones were associated with nalA (all comparison drugs), nalB and nalC (nalidixic acid) and nalD (ofloxacin, ciprofloxacin and nalidixic acid).
Effect of ciprofloxacin resistance on potency
Changes in the potency of the quinolones relative to each other were detected by comparing differences between their MIC 50 s and MIC 90 s in Table I . In this analysis, the MIC 90 s of Du-6859a increased least, indicating that it was the quinolone least affected by the mechanisms responsible for high-level resistance, while ciprofloxacin was the agent most affected. The relative potencies of the quinolones against organisms with varying levels of quinolone resistance were examined in more detail with staphylococci. Analysis of the cumulative susceptibilities of three groups of staphylococci, susceptible, moderately resistant and highly resistant strains, showed that against ciprofloxacin-susceptible (MIC 0.25 mg/L) isolates of S. aureus (Figure 1a ), Du-6859a was four to eight times more potent than temafloxacin, and eight to 16 times more potent than ofloxacin or ciprofloxacin. However, against highly resistant isolates (ciprofloxacin MIC 8 mg/L) Du6859a was 32 times more potent than temafloxacin, 32-64 times more potent than ofloxacin, and 64-128 times more potent than ciprofloxacin (Figure 1c ). This indicated that resistance increased less to Du-6859a than to the comparator quinolones. A similar trend was detected with coagulase-negative staphylococci (data not shown), with Du-6859a again being the most active quinolone and the least affected by increasing quinolone resistance.
Mutational frequencies
The ability of the quinolones to select less susceptible single-step mutants was determined by exposing 15 isolates to superinhibitory concentrations (two to eight times the MIC) of each quinolone. Forty-two of the mutants were Gram-positive and 26 were Gram-negative. Mutants at least four times less susceptible than the parental strain to at least one quinolone were selected from 80% of the strains exposed to ciprofloxacin, 71% of strains exposed to temafloxacin, 67% of strains exposed to Du-6859a, 53% of strains exposed to ofloxacin and each of the four strains exposed to nalidixic acid (Table IV) . Mutational frequencies of 10 8 -10 6 were obtained for 57 (84%) of the 68 single-step mutants selected by these quinolones.
Of the 68 mutants, the percentages of mutants inhibited by 1 mg/L of Du-6859a or the susceptible breakpoint of the other quinolones were: Du-6859a, 67%; ofloxacin, 43%; temafloxacin, 35%; and ciprofloxacin, 26%. None of the mutants was inhibited by <16 mg/L of nalidixic acid.
Less susceptible mutants of S. pneumoniae 211 could only be selected with ciprofloxacin, and then only at 2 MIC (frequency 10 6 ). Exposure to superinhibitory concentrations of the other quinolones did not yield less susceptible mutants. These large increases in quinolone MIC occurred most frequently with nalidixic acid (52% of all mutants exhibited 16-fold increased in MIC) and less frequently with the other quinolones: ciprofloxacin (37%), temafloxacin (23%), oflo x a c i n (19%) and Du-6859a (16%). When the drugs that selected this subset of mutants were examined, nalidixic acid selected the highest percentage of these mutants (35%). The percentages for the other quinolones were ciprofloxacin, 22%; temafloxacin, 20%; Du-6859a, 16%; and ofloxacin, 6%. Representative parents and mutants exhibiting large increases in at least one quinolone MIC are shown in Table V .
Bactericidal activity against enterococci
The results of the time-kill experiments with E. faecalis 103 and E. faecium 129 are shown in Figures 2 and 3 , respectively. Du-6859a, ofloxacin and ciprofloxacin were slowly bactericidal ( 3 log 10 decrease in viable count) only at 4 MIC. These concentrations were at or above resistant breakpoints of ofloxacin (8 mg/L) and ciprofloxacin (4 and 8 mg/L). For Du-6859a, 0.5 mg/L was bactericidal for both strains, with approximately 14 h exposure required for the detection of bactericidal activity against E. faecalis 103 (Figure 2 ) and 6 h exposure required for E. faecium 129 (Figure 3 ). These results indicated that Du-6859a was the most rapidly bactericidal quinolone.
At the MIC of each agent, less susceptible mutants were selected from E. faecalis 129. In tests with E. faecium at the MIC of each drug, only Du-6859a reduced the viable count during the first 6 h, but after this period outgrowth of a less susceptible mutant was detected. In contrast ofloxacin and ciprofloxacin were bacteriostatic for 6 h at the MIC, after which viable counts increased.
Discussion
Recent uncritical use of quinolones in the USA and other countries has resulted in the emergence of quinolone resistance at rates greater than originally anticipated. 6, [8] [9] [10] [11] Therefore, when new quinolones are evaluated it is important to take into account both activity against isolates that are resistant to currently available quino- lones, and the potential for susceptible isolates to develop resistance.
In this study Du-6859a was more potent than the comparator quinolones against all groups of bacteria tested, and was least affected by the mechanisms of quinolone resistance encountered. This finding was consistent with the data of Nakane et al., 12 but contrasted with the report of Marshall & Jones, 13 who observed that Du-6859a and ciprofloxacin were comparable in activity against recent clinical isolates from the family Enterobacteriaceae. This discrepancy may have occurred because the current study, and that of Nakane et al., contained more isolates with high-level ciprofloxacin resistance, whereas the Marshall & Jones study contained only few isolates with lowlevel ciprofloxacin resistance, and none with high-level resistance.
In time-kill studies, Du-6859a was the most rapidly bactericidal quinolone against the two enterococcal strains, but none of the quinolones exhibited the rapidly lethal activity that is characteristic of Du-6859a and other quinolones against more susceptible bacteria.
14 None of the study quinolones may have been sufficiently bactericidal for monotherapy in serious infections caused by E. faecalis or E. faecium.
In the in-vitro mutational studies Du-6859a inhibited more mutants at a concentration of 1 mg/L than did the comparator quinolones at their susceptible breakpoints. Du-6859a was also the quinolone to which the lowest percentage of mutants exhibited large ( 16-fold) MIC increases.
These features suggest that if serum and body fluid concentrations >1 mg/L can be achieved safely, Du-6859a may be more likely than currently available quinolones to retain activity against populations of bacteria that contain less susceptible strains due to previous exposure to quinolones. 
